Navigation Links
Stanmore Receives US FDA Approval for its JTS Non-invasive Extendible Implant
Date:6/24/2011

LONDON, June 24, 2011 /PRNewswire/ --


 

Stanmore Implants ("Stanmore"), specialists in the design and manufacture of patient specific implants for complex orthopaedic reconstructions, announces that it has received US FDA 510k approval for its Juvenile Tumour System ("JTS") non-invasive extendible distal femoral replacement ("JTS implant"), for use in paediatric orthopaedic oncology surgery.  

The JTS implant is used to replace large sections of the distal femur (thigh bone) that has been removed during surgery, often to treat cancer. Previously patients had to undergo multiple, painful surgeries in order to lengthen their implants as they grew. The JTS implant uses an electromagnetic device in order to lengthen the prosthesis without the need for surgery, anaesthesia or sedation, thus reducing the risk of complications.

In November 2002 the first patient, a 13-year-old girl received the JTS non-invasive extendible implant in the UK. Today she has reached skeletal maturity with legs of equal length. Since then over 240 devices have been implanted at specialist centres in 15 countries worldwide. Each implant is designed and manufactured specifically for the recipient patient by the team at Stanmore.

The JTS implant also has significant health economic benefits. A recent US study identified that it costs US$267 to undertake a non-invasive lengthening procedure compared to approximately US$8,000 if surgery is required. Lengthening procedures are undertaken regularly and can be undertaken in doctors' surgeries or outpatient departments.

Brian Steer, Executive Chairman of Stanmore, said:

"Gaining approval in the key US market is a major achievement for Stanmore. Having used the product for nine years in the European markets we are absolutely confident of the product's ability to significantly improve patient outcomes and quality of life by negating the need for repeated surgery in children. This has very clear health economic repercussions and as such we look forward to introducing this product in the United States during the next few months."

Stanmore is now focused on introducing this product across the US and is in the process of assembling a specialist sales team to market the product to orthopaedic oncology surgeons.

Notes to Editors

Stanmore Implants Worldwide

Stanmore Implants Worldwide is an innovative orthopaedic business focused on the design and manufacture of both bespoke and modular implants for limb sparing and complex primary and revision joint replacement.

Stanmore designs, manufactures and markets a custom implant service alongside a portfolio of orthopaedic implants for limb salvage and complex joint replacement, and is known for creating some of the world's most successful implants.

Stanmore acquired its robotic bone preparation technology through the acquisition of Acrobot, a medical devices company specialising in computer assisted orthopaedic surgery in August 2010.


'/>"/>
SOURCE Stanmore Implants
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine ... focus on preventative care with all my patients to alleviate possible future issues. I am ... to contact my office and my trained staff will assist you in any way possible.” ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
Breaking Medicine News(10 mins):